Hu Y. et al. (2014) found that GAPLINC is highly expressed in gastric cancer and can be used as a prognostic marker. The lower expression level of GAS5 in gastric cancer is also associated with poor prognosis (Sun et al., 2014). To obtain higher diagnostic accuracy and prognostic predictive effects, some studies have focused on combining multiple lncRNAs into a more efficient biomarker, such as the groups CTD-2616J11.14, RP1-90G24.10, RP11-150O12.3, RP11-1149O23.2, and MLK7-AS1 (Ren et al., 2016). This evidence concerns the gene GAS5 and gastric cancer.